Skip to main content
. 2015 Aug 21;12(8):10039–10055. doi: 10.3390/ijerph120810039

Figure 2.

Figure 2

Forest plot of the serum HBeAg loss of combination therapy group vs. nucleoside analogues monotherapy group. Eleven trials reported the serum HBeAg loss rate of chronic hepatitis B patients. A higher potent of HBeAg loss was shown in combination group than in monotherapy group. The highest was combination group vs. Adv group (RR = 2.87, 95% CI = 1.73–4.77, p < 0.001). Total risk ratio was 1.73 (95% CI = 1.32–2.26, p < 0.001).